| Product Name | Cosmetic Grade Cagrilintide peptide Raw Material Peptide CAS 1415456-99-3 |
|---|
| Appearance | Off-white fine powder |
| origin | China |
| Keywords | Peptides |
| Identify | Infrared absorption |
| Grade | Cosmetic Grade |
| Assay | ≥98.0% |
| Storage | Cool Dry Place |
| MOQ | 1 box |
| payment method | Bank transfer, Western Union remittance, express money and Bitcoin |
Cagrilintide is a new long-acting acylated amylin analog under development, mainly used as a non-selective amylin receptor (AMYR) and calcitonin G protein-coupled receptor (CTR) agonist. Its main functions and effects include:
Weight loss: Cagrilintide significantly reduces food intake and weight loss by activating amylin receptors and calcitonin G protein-coupled receptors, showing potential in obesity research.
Reducing food intake: The drug can suppress appetite and effectively delay gastric emptying, thereby reducing food intake.
Improving blood sugar control: When Cagrilintide is used in combination with the GLP-1 receptor agonist Semaglutide, it shows a more significant improvement in glycated hemoglobin levels, but the effect on HbA1c levels is not as good as using Semaglutide alone.
Treatment of obesity and type 2 diabetes: CagriSema (cagrilintide and semaglutide combination therapy) is designed for once-weekly subcutaneous injection and is primarily used to treat obesity, type 2 diabetes and metabolic dysfunction-associated steatohepatitis (MASH).
Prevention of weight regain: CagriSema may help prevent the "yo-yo effect" in which patients regain weight after stopping medication.
Our Main Product
China
